Simplifying US Healthcare is Something Jennifer Watts of Children’s Mercy Kansas City Would Like to Change About the Industry

Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.

Over the next five years, list prices of protected prescription drugs are expected grow between 1% and 4% a year, while net prices are expected to decline by the same amount, IQVIA predicts.

In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.

PrEP could work for women too, but there's a gap in HIV rates among this demographic, especially Black women. Outside of PrEP's proven effectiveness, the below facts suggest the need for better promotion and more options.